Chiesi has a passionate commitment to innovation in terms of both active ingredients and new formulations. In 2018 Chiesi is the 1^st Italian pharmaceutical company in Europe for patent deposits. More than 3,754 worldwide patents in the Chiesi portfolio.

In 2018, investment in R&D continued to grow – the expenditure exceeded €381.8 million, equating to €1.05 million per day and 21.6% of Chiesi Group revenues.

Our Research and Development team represents a fundamental asset in our business. It comprises integrated functional areas business areas (focussing on pipeline projects), which include:

• Discovery and Preclinical Research
• Chemistry and Manufacturing Controls
• Drug Delivery Technology
• Clinical Development
• Regulatory Affairs
• Pharmacovigilance
• Intellectual Property
• Quality Assurance
• Project Management and Leadership
• Research and Development Portfolio Management. 

Moreover, research and development functions also support products already on the market through pharmacovigilance and regulatory activities as well as active life cycle management programs.

Our traditional research and development focus is now complemented by new areas of research and expertise in various sectors: rare diseases, biotechnology and transplantology.

UK-CHI-2300297 May 2023